Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2023

Open Access 01-12-2023 | Polycystic Ovary Syndrome | Research

N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS)

Authors: Sihan Zhou, Rui Hua, Song Quan

Published in: Journal of Ovarian Research | Issue 1/2023

Login to get access

Abstract

Background

Polycystic ovary syndrome (PCOS) is a multisystem-related disease whose pathophysiology is still unclear. Several regulators of N6-methyladenosine (m6A) modification were confirmed to play a regulatory role in PCOS. Nonetheless, the roles of m6A regulators in PCOS are not fully demonstrated.

Materials and methods

Four mRNA expression profiling microarrays were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed m6A regulators between PCOS and normal patients were identified by R software. A random forest modal and nomogram were developed to assess the relationship between m6A regulators and the occurrence risk of PCOS. A consensus clustering method was utilized to distinctly divide PCOS patients into two m6A subtypes (m6A cluster A/B). The patterns of differential expression and immune infiltration were explored between the two m6A clusters.

Results

In this study, 22 significant m6A regulators were identified between healthy controls and PCOS patients. The random forest model determined three optimal m6A regulators which are related to the occurrence risk of PCOS, including YTHDF1, RBM15 and METTL14. A nomogram was established based on these genes, and its predictive reliability was validated by decision curve analysis. The consensus clustering algorithm distinctly divided PCOS cases into two m6A subtypes. The ssGSEA algorithm found that the immune infiltration was markedly enriched in m6A cluster B than in cluster A. The m6A-pattern related differentially expressed genes (DEGs) of the two m6A subtypes were demonstrated by differential expression analysis. We found that they were enriched in immune-related genes and various infection pathways. Based on the m6A-pattern related DEGs, the PCOS patients were classified into two m6A-pattern related genomic subtypes (gene clusters A and B).

Conclusions

The present study provided evidence concerning the different modification patterns of m6A regulators in PCOS compared with normal patients. This study will help clarify the overall impact of m6A modification patterns and related immune infiltration on PCOS.
Literature
1.
2.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.PubMedCrossRef
3.
Walters KA, Moreno-Asso A, Stepto NK, Pankhurst MW, Rodriguez PV, Rodgers RJ. Key signalling pathways underlying the aetiology of polycystic ovary syndrome. J Endocrinol. 2022;255(1):R1–26.PubMedCrossRef
4.
Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 2022;39(11):2439–73.PubMedCrossRef
5.
Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90(5):2545–9.PubMedCrossRef
6.
Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–5.PubMedPubMedCentralCrossRef
7.
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149(7):1635–46.PubMedPubMedCentralCrossRef
8.
Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–6.PubMedCrossRef
9.
Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–24.PubMedCrossRef
10.
Hu Y, et al. New sights in cancer: Component and function of N6-methyladenosine modification. Biomed Pharmacother. 2020;122: 109694.PubMedCrossRef
11.
Arguello AE, DeLiberto AN, Kleiner RE. RNA Chemical Proteomics Reveals the N(6)-Methyladenosine (m(6)A)-Regulated Protein-RNA Interactome. J Am Chem Soc. 2017;139(48):17249–52.PubMedCrossRef
12.
Huang H, Weng H, Chen J. The Biogenesis and Precise Control of RNA m(6)A Methylation. Trends Genet. 2020;36(1):44–52.PubMedCrossRef
13.
Liu H, Zheng J, Liao A. The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface. Front Immunol. 2022;13: 988130.PubMedPubMedCentralCrossRef
14.
Sui X, Klungland A, Gao L. RNA m6A modifications in mammalian gametogenesis and pregnancy. Reproduction. 2023;165(1):R1–8.PubMedCrossRef
15.
Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS, Zou C. RNA methylation and cancer treatment. Pharmacol Res. 2021;174: 105937.PubMedCrossRef
16.
Wei B, et al. N(6)-Methyladenosine RNA modification: a potential regulator of stem cell proliferation and differentiation. Front Cell Dev Biol. 2022;10: 835205.PubMedPubMedCentralCrossRef
17.
18.
Sun X, Lu J, Li H, Huang B. The role of m(6)A on female reproduction and fertility: from gonad development to ovarian aging. Front Cell Dev Biol. 2022;10: 884295.PubMedPubMedCentralCrossRef
19.
Barrett T, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991–5.PubMed
20.
Popovic M, Sartorius G, Christ-Crain M. Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1? Semin Immunopathol. 2019;41(4):447–59.PubMedCrossRef
21.
Yang Y, Qiao J, Tang RX, Li MZ. Genotype and haplotype determination of interleukin (IL) 1 beta (g. -511C>T and g. +3954C>T) and IL-1RN in polycystic ovary syndrome. Fertil Steril. 2010;94(1):384–6.PubMedCrossRef
22.
Wang C, et al. LncRNA GAS5 is upregulated in polycystic ovary syndrome and regulates cell apoptosis and the expression of IL-6. J Ovarian Res. 2020;13(1):145.PubMedPubMedCentralCrossRef
23.
Li Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–75.PubMedCrossRef
24.
Zhang S, Deng W, Liu Q, Wang P, Yang W, Ni W. Altered m(6) A modification is involved in up-regulated expression of FOXO3 in luteinized granulosa cells of non-obese polycystic ovary syndrome patients. J Cell Mol Med. 2020;24(20):11874–82.PubMedPubMedCentralCrossRef
25.
Zhou L, et al. N6-methyladenosine Demethylase FTO induces the dysfunctions of ovarian granulosa cells by upregulating Flotillin 2. Reprod Sci. 2022;29(4):1305–15.PubMedCrossRef
26.
Haouzi D, Assou S, Monzo C, Vincens C, Dechaud H, Hamamah S. Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome. Hum Reprod. 2012;27(12):3523–30.PubMedCrossRef
27.
Magoffin DA, San RG, Muderspach LI. Insulin-like growth factor binding proteins in a natural pre-ovulatory follicle from a woman with polycystic ovary syndrome. Hum Reprod. 1995;10(9):2248–52.PubMedCrossRef
28.
Kwon H, Choi DH, Bae JH, Kim JH, Kim YS. mRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome according to oocyte maturity. Fertil Steril. 2010;94(6):2417–20.PubMedCrossRef
29.
Yu XX, et al. Ascorbic acid induces global epigenetic reprogramming to promote meiotic maturation and developmental competence of porcine oocytes. Sci Rep. 2018;8(1):6132.PubMedPubMedCentralCrossRef
30.
Zheng H, et al. Decreased expression of programmed death Ligand-L1 by Seven in Absentia homolog 2 in Cholangiocarcinoma enhances T-Cell-mediated antitumor activity. Front Immunol. 2022;13: 845193.PubMedPubMedCentralCrossRef
31.
32.
Kontur C, Jeong M, Cifuentes D, Giraldez AJ. Ythdf m(6)A Readers Function Redundantly during Zebrafish Development. Cell Rep. 2020;33(13):108598.PubMedCrossRef
33.
Li X, Tian G, Wu J. Novel circGFRα1 promotes self-renewal of female germline stem cells mediated by m(6)A writer METTL14. Front Cell Dev Biol. 2021;9: 640402.PubMedPubMedCentralCrossRef
34.
Raffel GD, et al. Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen. Mol Cell Biol. 2009;29(2):333–41.PubMedCrossRef
35.
Luan YY, Zhang L, Peng YQ, Li YY, Liu RX, Yin CH. Immune regulation in polycystic ovary syndrome. Clin Chim Acta. 2022;531:265–72.PubMedCrossRef
36.
37.
38.
Qu J, et al. Discovery of immune-related diagnostic biomarkers and construction of diagnostic model in varies polycystic ovary syndrome. Arch Gynecol Obstet. 2022;306(5):1607–15.PubMedCrossRef
39.
Gao Q, et al. Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure. Front Endocrinol (Lausanne). 2022;13: 946504.PubMedCrossRef
40.
Na Z, Guo W, Song J, Feng D, Fang Y, Li D. Identification of novel candidate biomarkers and immune infiltration in polycystic ovary syndrome. J Ovarian Res. 2022;15(1):80.PubMedPubMedCentralCrossRef
41.
42.
de Alencar JB, Alves HV, Elpidio LN, Visentainer JE, Sell AM. Polymorphisms of cytokine genes and Polycystic Ovary Syndrome: a review. Metab Syndr Relat Disord. 2016;14(10):468–74.PubMedCrossRef
43.
Zhai Y, Pang Y. Systemic and ovarian inflammation in women with polycystic ovary syndrome. J Reprod Immunol. 2022;151: 103628.PubMedCrossRef
44.
Metadata
Title
N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS)
Authors
Sihan Zhou
Rui Hua
Song Quan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2023
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-023-01147-9

Other articles of this Issue 1/2023

Journal of Ovarian Research 1/2023 Go to the issue

Research

Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors

Research

Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy

Research

Identification of transcriptome characteristics of granulosa cells and the possible role of UBE2C in the pathogenesis of premature ovarian insufficiency

Research

CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer

Research

MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer

Research

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer